UAE High-Throughput Screening (HTS) Market (2026-2031)
The UAE High-Throughput Screening (HTS) Market was valued at $392.1 Million in 2026 and projected to reach to $502.8 Million by 2031, representing a compound annual growth rate of 8.7%. The UAE High-Throughput Screening market is poised for sustained growth, supported by the nation's strategic positioning as a life sciences hub in the Middle East.
UAE High-Throughput Screening (HTS) Market Trends and Insights
- This 8.7% compound annual growth rate reflects increasing adoption of HTS technologies across pharmaceutical research, biotechnology, and contract research organizations throughout Rest Of Latin America.
- The region's growth trajectory is supported by rising investment in drug discovery infrastructure and growing demand for efficient screening methodologies. Rest Of Latin America is experiencing accelerating modernization of laboratory capabilities and heightened focus on precision medicine initiatives.
- Between 2026 and 2031, Rest Of Latin America's market will benefit from expanded access to automation technologies and improved funding for life sciences research.
- The region's pharmaceutical and biotech sectors are increasingly recognizing HTS as essential for competitive drug development pipelines, driving sustained market penetration across Rest Of Latin America. Key market participants in Rest Of Latin America are investing in localized solutions and partnerships to capture emerging opportunities.
- Rest Of Latin America's regulatory environment and growing scientific workforce are creating favorable conditions for HTS adoption, positioning the region as a developing hub for high-throughput research activities within the broader Latin American landscape..
Key Market Statistics
- CAGR (2026-2031) 8.7% CAGR
- Market Size, 2026 ~USD 392.1 Million
- Forecast, 2031 ~USD 502.8 Million
- Country UAE
UAE High-Throughput Screening (HTS) Market Overview
Market Size & Growth :
UAE's High-Throughput Screening market is valued at USD 392.1 million in 2026, with projections reaching USD 502.8 million by 2031, representing a robust 8.7% CAGR driven by pharmaceutical innovation and biotech expansion.
Regional Investment Momentum :
UAE is experiencing accelerated adoption of HTS technologies through government-backed healthcare initiatives, including the Dubai Health Authority and Abu Dhabi's life sciences clusters, positioning the nation as a regional innovation hub.
Pharmaceutical & Biotech Growth :
The UAE's pharmaceutical sector is expanding rapidly with increased R&D investments from multinational companies and local biotech startups, driving demand for high-throughput screening solutions in drug discovery and development.
Contract Research Organization Expansion :
CROs operating in UAE are scaling operations to support regional and international pharmaceutical clients, creating significant demand for advanced HTS platforms and automation technologies.
UAE High-Throughput Screening (HTS) Market Dynamics
- Government initiatives promoting healthcare innovation, coupled with increased foreign direct investment in pharmaceutical research, are driving adoption of advanced HTS technologies across the region.
- The 8.7% CAGR reflects growing demand from pharmaceutical companies, biotechnology firms, and contract research organizations seeking to accelerate drug discovery timelines and improve research efficiency. Looking ahead to 2031, UAE's HTS market will benefit from expanding healthcare infrastructure, rising R&D budgets, and the establishment of specialized research facilities in Dubai and Abu Dhabi.
- The convergence of regulatory support, skilled workforce development, and technology partnerships with global leaders positions UAE as an increasingly attractive destination for high-throughput screening investments and operations..
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Key Takeaways
- Rest Of Latin America's HTS market will grow from USD 392.1M (2026) to USD 502.8M (2031) at an 8.7% CAGR.
- Rest Of Latin America is experiencing increased pharmaceutical and biotech investment driving HTS technology adoption.
- Rest Of Latin America's modernizing laboratory infrastructure and scientific workforce support sustained market expansion.
- Rest Of Latin America represents a developing regional hub for high-throughput screening within Latin America.
High-Throughput Screening (HTS) Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | LIQUID HANDLING SYSTEMS (Application) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 10.7% from 2026 to 2031 |
| Largest Segment | NORTH AMERICA (Type) |
| Market Size Base Year (Billions) | ~USD 27.61 (2026) |
| Revenue Forecast (Billions) | ~USD 45.9 (2031) |
| Segments Covered | Type, Application, Technology |
UAE High-Throughput Screening (HTS) Market Report Segmentation
3 segment dimensions are covered across the global market.
By Type
- 2D Cell Cultures
- 3D Cell Cultures
- Alginate/Agarose
- Animal-Derived Hydrogels
- Collagen
- Detection Systems
- Hydrogels
- Imaging Instruments
- Inert Matrix/Solid Scaffolds
- Laboratory Consumables
- Liquid Handling Systems
- Matrigel
- Micropatterned Surfaces
- Other Instruments
- Perfusion Cell Cultures
- Reagents & Assay Kits
- Reporter-Based Assays
- Scaffold-Based Technology
- Scaffold-Free Technology
- Synthetic Hydrogels
By Application
- Biochemical Screening
- Drug Discovery
- Life Science Research
- Other Applications
By Technology
- Cell-Based Assays
- Lab-On-A-Chip
- Label-Free Technology
Target Audience
- Pharmaceutical Companies : UAE-based and regional pharmaceutical firms need HTS market intelligence to optimize drug discovery investments, evaluate technology solutions, and benchmark R&D productivity against regional competitors.
- Biotechnology Firms : Biotech startups and established companies in UAE require market data to secure funding, plan technology infrastructure, and identify collaboration opportunities with research institutions and CROs.
- Contract Research Organizations : CROs operating in UAE need detailed market insights to expand service offerings, invest in HTS capabilities, and position themselves competitively for pharmaceutical client contracts across the region.
- Healthcare Technology Vendors : HTS equipment and software providers need UAE-specific market analysis to develop localized solutions, identify customer segments, and establish distribution partnerships with regional healthcare organizations.
- Government & Policy Makers : UAE healthcare authorities and economic development agencies require market intelligence to inform life sciences strategy, allocate R&D funding, and attract pharmaceutical investments to the emirate.
Key Companies in the UAE High-Throughput Screening (HTS) Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| BIOCARTIS SA | Belgium | Private Company | Oncology assay consumables,Instrument systems and service,Other legacy and residual activities, |
| QIAGEN NV | Netherlands | Public Company | Sample technology consumables and instruments,Molecular diagnostics assays (TB, oncology, sexual and reproductive health, viral load),PCR and enzyme solutions (qPCR, dPCR, RT-PCR, configured enzymes), |
| CODEXIS, INC. | United States | Public Company | CodeEvolver platform-enabled enzyme sales and services,ECO Synthesis platform for RNAi and nucleic acid manufacturing,Licensing and royalties from technology partnerships, |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing, single-use, filtration, aseptic fill-finish),Life Sciences (analytical instruments, genomics, lab automation),Diagnostics (clinical instruments, consumables, software, services), |
| MERCK KGAA | Germany | Public Company | Life Science,Healthcare,Electronics, |
| AGILENT TECHNOLOGIES, INC. | United States | Public Company | Life Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets, |
| REVVITY, INC. | United States | Public Company | Diagnostics (prenatal, neonatal, infectious disease, immunodiagnostics),Life science reagents and assays (BioLegend, Dharmacon, Alpha platforms),Instruments and imaging systems, |
| TECAN GROUP LTD. | Switzerland | Public Company | Liquid handling and automation platforms (incl. Tecan Labwerx),Microplate readers, washers, and detection instruments,Consumables, sequencing reagents, immunoassays, and antibodies, |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Clinical Diagnostics systems, kits, and quality controls,Life Science instruments and reagents,Informatics and software, |
| CORNING INCORPORATED | United States | Public Company | Optical communications (fiber, cable, hardware, connectivity),Display glass substrates (LCD and OLED),Specialty materials and mobile consumer electronics glass, |
| METTLER-TOLEDO INTERNATIONAL INC. | Switzerland | Public Company | Laboratory instruments and LabX software,Industrial instruments and product inspection,Retail weighing and fresh-goods solutions, |
| LONZA GROUP | Switzerland | Public Company | Integrated Biologics,Advanced Synthesis (small molecules, ADCs, HPAPIs),Specialized Modalities (cell & gene, microbial, bioscience, mRNA), |
| WATERS CORPORATION | United States | Public Company | Liquid Chromatography Systems and Columns,Mass Spectrometry Systems,TA Instruments (Thermal, Rheometry, Calorimetry), |
| SARTORIUS AG | Germany | Public Company | Bioprocess solutions (bioreactors, filtration, chromatography, fluid management),Lab products and services (weighing, pipettes, filtration, microbiological testing),Advanced analytical and cell analysis systems (BLI, SPR, cytometry, live-cell imaging), |
| EPPENDORF SE | Germany | Private Company | Liquid handling (pipettes, dispensers, automated systems),Separation & instrumentation (centrifuges, PCR cyclers, ULT freezers),Consumables (tubes, tips, plates, single-use bioreactors), |
| PORVAIR PLC | United Kingdom | Public Company | Aerospace & Industrial Filtration,Laboratory Instruments and Consumables,Metal Melt Quality (Porous Ceramic Filters), |
BIOCARTIS SA
BIOCARTIS SA is a Belgian private company established in 2014 with 500 employees. The company focuses on molecular diagnostics and personalized medicine solutions.
QIAGEN NV
QIAGEN NV is a Dutch public company founded in 1984 with 5,500 employees. The company is a leading provider of molecular diagnostics, sample preparation, and life sciences research tools.
CODEXIS, INC.
CODEXIS, INC. is a United States public company founded in 2002 with 146 employees. The company develops enzyme engineering and biocatalysis solutions for pharmaceutical and industrial applications.
THERMO FISHER SCIENTIFIC INC.
THERMO FISHER SCIENTIFIC INC. is a United States public company founded in 1956 with 125,000 employees. The company is a global leader in serving science with a broad portfolio of laboratory equipment, reagents, and services.
DANAHER CORPORATION
DANAHER CORPORATION is a United States public company founded in 1969 with 59,000 employees. The company operates a diversified conglomerate with significant presence in life sciences, diagnostics, and environmental solutions.
MERCK KGAA
MERCK KGAA is a German public company founded in 1668 with 59,077 employees. The company is a global science and technology leader operating in pharmaceuticals, life sciences, and performance materials.
AGILENT TECHNOLOGIES, INC.
AGILENT TECHNOLOGIES, INC. is a United States public company founded in 1999 with 18,000 employees. The company provides analytical instruments, software, and services for life sciences, diagnostics, and applied chemical markets.
REVVITY, INC.
REVVITY, INC. is a United States public company founded in 1937 with 11,000 employees. The company develops and manufactures analytical instruments and software for life sciences research and diagnostics.
TECAN GROUP LTD.
TECAN GROUP LTD. is a Swiss public company founded in 1980 with 3,166 employees. The company specializes in laboratory automation and detection solutions for life sciences and diagnostics applications.
BIO-RAD LABORATORIES, INC.
BIO-RAD LABORATORIES, INC. is a United States public company founded in 1952 with 7,450 employees. The company manufactures and distributes life science research products and clinical diagnostics solutions.
CORNING INCORPORATED
CORNING INCORPORATED is a United States public company founded in 1851 with 67,200 employees. The company is a diversified technology leader with significant operations in life sciences, laboratory products, and specialty materials.
METTLER-TOLEDO INTERNATIONAL INC.
METTLER-TOLEDO INTERNATIONAL INC. is a Swiss public company founded in 1991 with 16,600 employees. The company manufactures precision instruments and services for laboratory, industrial, and retail applications.
LONZA GROUP
LONZA GROUP is a Swiss public company founded in 1897 with 20,000 employees. The company is a leading supplier of products and services for the pharmaceutical, biotech, and specialty chemical industries.
WATERS CORPORATION
WATERS CORPORATION is a United States public company founded in 1958 with 7,900 employees. The company develops and manufactures analytical instruments and software for laboratory and life sciences applications.
SARTORIUS AG
SARTORIUS AG is a German public company founded in 1870 with 14,242 employees. The company provides laboratory and process technologies for pharmaceutical, biotech, and food industries.
EPPENDORF SE
EPPENDORF SE is a German private company founded in 1945 with 4,358 employees. The company manufactures laboratory equipment and consumables for life sciences research and diagnostics.
PORVAIR PLC
PORVAIR PLC is a United Kingdom public company founded in 1982 with 992 employees. The company manufactures advanced filtration and separation products for life sciences and industrial applications.
Reasons to Buy this Report
- Market Entry Strategy : Gain comprehensive insights into UAE's HTS market dynamics, competitive landscape, and growth drivers to develop informed market entry strategies and identify partnership opportunities with local pharmaceutical and biotech players.
- Investment Decision Support : Access detailed market sizing, forecasts, and trend analysis to support capital allocation decisions for establishing HTS facilities, acquiring technology platforms, or expanding operations in the UAE region.
- Competitive Intelligence : Understand key market players, technology adoption rates, and competitive positioning specific to UAE to benchmark performance and identify differentiation opportunities in the regional HTS market.
- Regulatory & Policy Insights : Obtain clarity on UAE's healthcare regulations, government initiatives, and R&D incentives that impact HTS market growth and operational requirements for pharmaceutical and biotech organizations.
- Customer Demand Analysis : Identify specific customer segments, their HTS technology requirements, and purchasing behaviors within UAE's pharmaceutical, biotech, and CRO sectors to optimize product offerings and sales strategies.
Frequently asked questions
What is the market size of HTS in Rest Of Latin America in 2026?
Rest Of Latin America's High-Throughput Screening market is valued at USD 392.1 million in 2026.
What is the projected market size for HTS in Rest Of Latin America by 2031?
Rest Of Latin America's HTS market is forecast to reach USD 502.8 million by 2031.
What is the CAGR for HTS in Rest Of Latin America?
Rest Of Latin America's HTS market is expected to grow at a compound annual growth rate of 8.7% from 2026 to 2031.
What factors are driving HTS market growth in Rest Of Latin America?
Rest Of Latin America's HTS market growth is driven by increased pharmaceutical investment, modernized laboratory infrastructure, expanding biotech sectors, and growing adoption of automation technologies for drug discovery.
How does Rest Of Latin America's HTS market compare to global trends?
Rest Of Latin America's 8.7% CAGR is slightly below the global average of 10.7%, reflecting the region's developing market status while still demonstrating strong growth potential within Latin America.
RESEARCH METHODOLOGY
This research study relied heavily on secondary sources, directories, and databases to identify and collect valuable information for analyzing the global high-throughput screening (HTS) market. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of leading market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with primary research inputs to arrive at the final market size.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive technical, market-oriented, and commercial study of the high-throughput screening (HTS) market. The secondary sources used for this study include World Health Organization (WHO), American Society for Clinical Laboratory Science (ASCLS), Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI), American Association for Clinical Chemistry (AACC), National Center for Advancing Translational Sciences (NCATS), American Society for Pharmacology and Experimental Therapeutics (ASPET), National Health Service (NHS), Pharmaceuticals and Medical Devices Agency (PMDA), European Medicines Agency (EMA), Society for Laboratory Automation and Screening (SLAS), European Bioinformatics Institute, and Center for Translational Research, among others. Corporate filings include annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations. Secondary data were collected and analyzed to determine the overall size of the global high-throughput screening (HTS) market, which was subsequently validated through primary research. These sources were also used to obtain key information on major players, market classification, and segmentation aligned with industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and to assess the market's future prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were employed to estimate and validate the overall size of the high-throughput screening (HTS) market. These methods were also widely used to determine the size of various market segments. The research methodology used to estimate the market size includes the following:
High-Throughput Screening (HTS) Market : Top-Down and Bottom-Up Approach
Data Triangulation
After estimating the overall market size, the total market was divided into segments and subsegments. Data triangulation and market breakdown techniques were used where applicable to finalize the overall market analysis and obtain precise statistics for all segments and subsegments. The data was triangulated by examining various factors and trends from both demand and supply sides.
Market Definition
High-throughput screening (HTS) is a drug discovery process that involves automated testing of large quantities of chemical or biological compounds against specific biological targets using various binding assays.
The HTS market comprises products (instruments, reagents & consumables, software), and services used to perform automated, parallel screening of large compound or biological libraries against defined biological targets or assays to identify active entities (hits). The high-throughput screening (HTS) market comprises workflow stages from assay development and compound library management to automated large-scale screening and hit identification, culminating in validated screening hits.
Key Stakeholders
- Contract research organizations
- Pharmaceutical & biopharmaceutical companies
- Academic & research institutes
- High-throughput screening instrument & reagent manufacturers
- High-content screening database, service, and software providers
- Venture capitalists & investors
- Market research & consulting firms
- Government associations
- Medical institutions & universities
Report Objectives
- To define, describe, and forecast the high-throughput screening (HTS) market by offering, products by type, products by technology, products by workflow, products by end user, services by type, services by end user, application, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall high-throughput screening (HTS) market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To profile the key players and analyze their market shares and core competencies2
- To track and analyze competitive developments, such as product & service launches, agreements, partnerships, acquisitions, and research & development activities
- To analyze and provide funding & investment activities, brand/product/service comparative analysis, and vendor valuation & financial metrics of the high-throughput screening (HTS) market
Customization Options
Based on the given market data, MarketsandMarkets offers customization to meet the company’s specific needs. The following customization options are available for this report:
Portfolio Assessment
- Product/Service Matrix gives a detailed comparison of the product/service portfolios of the top five companies.
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Geographical Analysis
- Further breakdown of the Rest of Europe high-throughput screening (HTS) market, by country
- Further breakdown of the Rest of Asia Pacific high-throughput screening (HTS) market, by country
- Further breakdown of the Rest of Latin America high-throughput screening (HTS) market, by country
Get the Full High-Throughput Screening (HTS) Market Report
Full forecast, segment splits, and company analysis for all High-Throughput Screening (HTS) Market.
- Canada High-Throughput Screening (HTS) Market
- US High-Throughput Screening (HTS) Market
- Germany High-Throughput Screening (HTS) Market
- UK High-Throughput Screening (HTS) Market
- France High-Throughput Screening (HTS) Market
- Italy High-Throughput Screening (HTS) Market
- Spain High-Throughput Screening (HTS) Market
- China High-Throughput Screening (HTS) Market
- Japan High-Throughput Screening (HTS) Market
- India High-Throughput Screening (HTS) Market
- Australia High-Throughput Screening (HTS) Market
- South Korea High-Throughput Screening (HTS) Market
- Brazil High-Throughput Screening (HTS) Market
- Mexico High-Throughput Screening (HTS) Market
- Saudi Arabia High-Throughput Screening (HTS) Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report